Standard BioTools (LAB) Scheduled to Post Quarterly Earnings on Wednesday

Standard BioTools (NASDAQ:LAB) will issue its quarterly earnings data after the market closes on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Standard BioTools has set its FY 2024 guidance at EPS.Parties interested in participating in the company’s conference call can do so using this link.

Standard BioTools (NASDAQ:LAB) last issued its earnings results on Wednesday, July 31st. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. The company had revenue of $37.21 million during the quarter, compared to analyst estimates of $48.15 million. Standard BioTools had a negative return on equity of 43.45% and a negative net margin of 87.05%. On average, analysts expect Standard BioTools to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Standard BioTools Trading Down 2.1 %

LAB stock opened at $1.84 on Wednesday. The stock’s 50 day simple moving average is $1.93 and its 200 day simple moving average is $2.14. Standard BioTools has a 12-month low of $1.21 and a 12-month high of $3.04. The firm has a market cap of $681.57 million, a P/E ratio of -1.82 and a beta of 1.58.

Analysts Set New Price Targets

Separately, TD Cowen dropped their target price on shares of Standard BioTools from $3.50 to $2.75 and set a “buy” rating on the stock in a report on Thursday, August 1st.

Insider Activity

In related news, Director Casdin Partners Master Fund, L purchased 150,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were acquired at an average price of $2.15 per share, with a total value of $322,500.00. Following the acquisition, the director now owns 53,775,821 shares in the company, valued at approximately $115,618,015.15. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders purchased 5,117,508 shares of company stock valued at $8,662,080. 53.10% of the stock is currently owned by insiders.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.